Click image to view original image
Hot Selling Factory Direct Supply Steroid Hormone Powder Ciclesonide
Product Details:
1,Manufacturer :holybiological
2,Molecular Formula:C32H44O7
3,Molecular Weight:540.69
4,Purity:99%
5, Character: White Crystalline Powder
6,Shipment: EMS, DHL, FedEx, TNT
Description:
Ciclesonide is a novel inhaled corticosteroid used in the continuous treatment of mild-to-severe asthma. Its formulation and mechanism of action yield a low oral and systemic bioavailability, and high pulmonary deposition. In multiple clinical trials, ciclesonide is at least as effective as either fluticasone propionate or budesonide at symptom control, while in many cases having improved safety outcomes and tolerability. The improved safety and comparable efficacy profiles of ciclesonide demonstrated in current studies could potentially yield a treatment option that may lead to improved adherence and outcome.
Ciclesonide (Alvesco®; Sepracor, Inc., Nycomed, Inc.) is a novel, new corticosteroid developed for the treatment of mild to severe persistent asthma. It is delivered by metered-dose inhaler (MDI) once daily or twice daily (dosing depends on country). This review will focus on the safety and efficacy profile of ciclesonide, as well as to establish its mechanism of action.
Ciclesonide ([R]-11β, 16α, 17, 21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde 21-isobutyrate; CIC) is inhaled into the lungs via hydrofluoroalkane-MDI (HFA-MDI), where it is converted by local esterases to its active metabolite, desisobutyryl-ciclesonide (des-CIC, Figure 1). Relative to dexamethasone (100), CIC has a low glucocorticoid receptor binding affinity of 12, while des-CIC has a significantly higher binding affinity of 1212.18,19 Studies demonstrate no conversion of R-CIC or des-CIC to the S-epimer in vivo, which has different physicochemical properties, and a markedly lower receptor affinity.20 Pharmacokinetic profiles of des-CIC were similar in comparative healthy and asthma patients, likely indicating that bronchial narrowing and airway inflammation do not affect the distribution of CIC and its subsequent activation to des-CIC in the lungs.21 An additional study also demonstrated equivalent PK/PD profiles of CIC-HFA when administered with and without a spacer.
Our advantages :
1)We specialize in this field for 9 year, have rich experience.
2)The purity of our product are all over 99%
3)Because we are factory direct sale, so we can give you a better price.
4)All the parcel can be sent in 24 hours after the payment, we guarantee 100% safe delivery.
If you are interested in our products, feel free to contact us:
Skype: holybiological02
